Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
minocycline (OraPharma, 268e2d)
- Development stage
- Approved
- Lead developer
- OraPharma
- Modality
- Small Molecules
- Administration
- Subgingival
01
Overview
ARESTIN (minocycline hydrochloride microspheres, 1 mg) is a locally applied, sustained-release antibiotic developed by OraPharma (now a subsidiary of Bausch Health) for the treatment of adult periodontitis. The product consists of minocycline hydrochloride, a tetracycline-class small molecule antibiotic, encapsulated within bioresorbable poly(glycolide-co-dl-lactide) (PGLA) microspheres. It is indicated as an adjunct to scaling and root planing (SRP) procedures for the reduction of pocket depth in patients with chronic periodontitis. Administered subgingivally by dental professionals, the microspheres provide a localized, high concentration of the antibiotic at the site of infection over an extended period. Minocycline exerts its antimicrobial activity by binding to the 30S ribosomal subunit, inhibiting bacterial protein synthesis in pathogens such as Porphyromonas gingivalis and Prevotella intermedia.
- Brand names
- ARESTIN
- Other names
- minocycline hydrochloride microspheresminocycline HCl microspheresminocycline hydrochloride
02
Targets
Bacterial Ribosome
Beyond the preview
Go deeper on minocycline (OraPharma, 268e2d).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on minocycline (OraPharma, 268e2d).